Association between Factor XIII Activity and Clinical Course in Pediatric Patients with Immunoglobulin A Vasculitis

Kobe J Med Sci. 2023 Aug 21;69(2):E57-E63.

Abstract

Background: Immunoglobulin A vasculitis is a systemic form of vasculitis that predominantly affects children. Factor XIII activity is decreased in some cases, and several reports have shown an association between abdominal pain and decreased factor XIII activity. However, the clinical significance of decreased factor XIII activity in pediatric immunoglobulin A vasculitis has not been fully elucidated. This study aimed to identify the association between factor XIII activity and the clinical course of pediatric patients with immunoglobulin A vasculitis.

Methods: Forty-four pediatric patients, admitted to Kita-Harima Medical Center with a clinical diagnosis of immunoglobulin A vasculitis between October 1, 2013 and September 30, 2022, were retrospectively reviewed, and 22 patients were analyzed. The patients' background characteristics and clinical course were compared between the normal and decreased factor XIII activity (<70%) groups.

Results: The group with decreased factor XIII activity showed a significantly increased duration of hospitalization (14 [6-36] vs. 7 [5-13] days, p = 0.01), total glucocorticoid dose (prednisolone 22.7 [4.9-55.5] vs. 10.1 [3.4-19.6] mg/kg, p = 0.02), and duration of glucocorticoid administration (19 [4-85] vs. 10 [3-15] days, p = 0.03). Correlational analyses showed that these three parameters were negatively correlated with factor XIII activity.

Conclusions: Factor XIII activity was negatively correlated with the duration of hospitalization, total glucocorticoid dose, and duration of glucocorticoid administration. Factor XIII activity is not only associated with abdominal symptoms but also may be a marker to predict the overall trajectory of acute-phase treatment in pediatric patients with immunoglobulin A vasculitis.

Keywords: Duration of glucocorticoid administration; Duration of hospitalization; Factor XIII; Immunoglobulin A vasculitis; Total glucocorticoid dose.

MeSH terms

  • Child
  • Disease Progression
  • Factor XIII*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin A
  • Retrospective Studies
  • Vasculitis* / drug therapy

Substances

  • Factor XIII
  • Glucocorticoids
  • Immunoglobulin A